EDRN Prostate MRI Biomarker Study

Summary

The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.

Conditions

• PSA
• Prostate Cancer

Interventions

DIAGNOSTIC_TEST

MRI prostate

MRI and laboratory biomarkers

Sponsors & Collaborators

• The University of Texas Health Science Center at San Antonio

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• University of Chicago

  collaborator OTHER

• Cornell University

  collaborator OTHER

• H. Lee Moffitt Cancer Center and Research Institute

  collaborator OTHER

• Vanderbilt University

  collaborator OTHER

• Emory University

  collaborator OTHER

• University of Miami

  collaborator OTHER

• University of Texas

  collaborator OTHER

• Beth Israel Deaconess Medical Center

  collaborator OTHER

• Brigham and Women's Hospital

  collaborator OTHER

• Fred Hutchinson Cancer Center

  collaborator OTHER

• University of Michigan

  lead OTHER

Principal Investigators

• John T Wei, MD, MS · University of Michigan

Eligibility

Min Age

18 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-02-04

Primary Completion

2028-06-30

Completion

2028-12-31

Countries

• United States

Study Locations